1887

Abstract

Parainfluenza virus type 3 (PIV3) and respiratory syncytial virus (RSV) are the main causes of ubiquitous acute respiratory diseases of infancy and early childhood, causing 20–25 % of pneumonia and 45–50 % of bronchiolitis in hospitalized children. The primary goal of this study was to create an effective and safe RSV vaccine based on utilizing attenuated bovine PIV3 (bPIV3) as a virus vector backbone. bPIV3 had been evaluated in human clinical trials and was shown to be attenuated and immunogenic in children as young as 2 months of age. The ability of bPIV3 to function as a virus vaccine vector was explored further by introducing the RSV attachment (G) and fusion (F) genes into the bPIV3 RNA genome. The resulting virus, bPIV3/RSV(I), contained an insert of 2900 nt, comprising two translationally competent transcription units. Despite this increase in genetic material, the virus replicated to high titres in Vero cells. This recombinant virus expressed the RSV G and F proteins sufficiently to evoke a protective immune response in hamsters upon challenge with RSV or human PIV3 and to elicit RSV neutralizing and PIV3 haemagglutinin inhibition serum antibodies. In effect, a bivalent vaccine was produced that could protect vaccinees from RSV as well as PIV3. Such a vaccine would vastly reduce the respiratory disease burden, the associated hospitalization costs and, most importantly, decrease morbidity and mortality of infants, immunocompromised individuals and the elderly.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19079-0
2003-08-01
2019-12-11
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/8/vir842153.html?itemId=/content/journal/jgv/10.1099/vir.0.19079-0&mimeType=html&fmt=ahah

References

  1. Beeler, J. A. & van Wyke Coelingh, K. ( 1989; ). Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63, 2941–2950.
    [Google Scholar]
  2. Chanock, R. M. & Murphy, B. R. ( 1991; ). Past efforts to develop safe and effective RSV vaccines. In Animal Models of Respiratory Syncytial Virus Infection, pp. 35–42. Edited by B. Meignier, B. Murphy & P. Ogra. Lyon: Merieux Foundation.
  3. Crowe, J. E., Jr, Bui, P. T., Davis, A. R., Chanock, R. M. & Murphy, B. R. ( 1994a; ). A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12, 783–790.[CrossRef]
    [Google Scholar]
  4. Crowe, J. E., Jr, Bui, P. T., London, W. T., Davis, A. R., Hung, P. P., Chanock, R. M. & Murphy, B. R. ( 1994b; ). Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12, 691–699.[CrossRef]
    [Google Scholar]
  5. Durbin, A. P., McAuliffe, J. M., Collins, P. L. & Murphy, B. R. ( 1999; ). Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 261, 319–330.[CrossRef]
    [Google Scholar]
  6. Falsey, A. R., Cunningham, C. K., Barker, W. H., Kouides, R. W., Yuen, J. B., Menegus, M., Weiner, L. B., Bonville, C. A. & Betts, R. F. ( 1995; ). Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 172, 389–394.[CrossRef]
    [Google Scholar]
  7. Hall, C. B. ( 1999; ). Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr 135, 2–7.
    [Google Scholar]
  8. Hall, C. B. ( 2001; ). Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344, 1917–1928.[CrossRef]
    [Google Scholar]
  9. Haller, A. A., Miller, T., Mitiku, M. & Coelingh, K. ( 2000; ). Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74, 11626–11635.[CrossRef]
    [Google Scholar]
  10. Haller, A. A., MacPhail, M., Mitiku, M. & Tang, R. S. ( 2001; ). A single amino acid substitution in the viral polymerase creates a temperature-sensitive and attenuated recombinant bovine parainfluenza virus type 3. Virology 288, 342–350.[CrossRef]
    [Google Scholar]
  11. Karron, R. A., Makhene, M., Gay, K., Wilson, M. H., Clements, M. L. & Murphy, B. R. ( 1996; ). Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 15, 650–654.[CrossRef]
    [Google Scholar]
  12. Karron, R. A., Wright, P. F., Crowe, J. E., Jr, Clements-Mann, M. L., Thompson, J., Makhene, M., Casey, R. & Murphy, B. R. ( 1997; ). Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 176, 1428–1436.[CrossRef]
    [Google Scholar]
  13. Martinez, I., Dopazo, J. & Melero, J. A. ( 1997; ). Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78, 2419–2429.
    [Google Scholar]
  14. Murphy, B. R., Hall, S. L., Kulkarni, A. B., Crowe, J. E., Jr, Collins, P. L., Connors, M., Karron, R. A. & Chanock, R. M. ( 1994; ). An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 32, 13–36.[CrossRef]
    [Google Scholar]
  15. Schmidt, A. C., McAuliffe, J. M., Huang, A., Surman, S. R., Bailly, J. E., Elkins, W. R., Collins, P. L., Murphy, B. R. & Skiadopoulos, M. H. ( 2000; ). Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin–neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74, 8922–8929.[CrossRef]
    [Google Scholar]
  16. Schmidt, A. C., McAuliffe, J. M., Murphy, B. R. & Collins, P. L. ( 2001; ). Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75, 4594–4603.[CrossRef]
    [Google Scholar]
  17. Schmidt, A. C., Wenzke, D. R., McAuliffe, J. M., St Claire, M., Elkins, W. R., Murphy, B. R. & Collins, P. L. ( 2002; ). Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 76, 1089–1099.[CrossRef]
    [Google Scholar]
  18. Skiadopoulos, M. H., Surman, S. R., Durbin, A. P., Collins, P. L. & Murphy, B. R. ( 2000; ). Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes. Virology 272, 225–234.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19079-0
Loading
/content/journal/jgv/10.1099/vir.0.19079-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error